PIPELINE

NPXe has several additional opportunities to explore. If the Phase III trial’s data support a neuroprotective effect of XENEX™ in hypoxic disease, then there are a number of potential applications and related indications which would lend themselves to the treatment including:

Portable Device

Following success in the hospital trial, which targets PCAS, NPXe intends to develop the use of XENEX™ in the pre-hospital emergency response setting by way of a portable device for use in an ambulance. Approximately 60 percent of OHCA patients (approximately 487,000 people in the EU and US) survive to be treated by emergency medical services (‘‘EMS’’) each year. As time to intervention is critical, administration of XENEX™ in the field may improve the performance of the therapy further.


Stroke

One indication which is particularly sensitive to the ‘time to treatment’ is stroke. The availability of a portable device could enable EMS to provide neuroprotectant XENEX™ at an early stage. Importantly, unlike current treatments, ,  there is no evidence to suggest that xenon interferes with the subsequent treatment pathway for either of the principal causes of stroke (ischaemia or harmorrhage) and could therefore be administered before the cause of the stroke is established. This means that the entire patient population suffering from stroke (some 795,000 in the US alone) could be eligible for XENEX™ treatment.

Researchers at Turku University Hospital in Finland will start a Phase II investigator-initiated study using XENEX™ in 2019 to evaluate the use of xenon gas in subarachnoid haemorrhage. As this is a narrow indication, it may result in a narrow approval. Nonetheless, this could provide data which will reduce the overall regulatory requirement for a broader stroke label and accelerate the development of an ambulance device.

In addition to the above, the following indications may also benefit from the neuroprotective effects of xenon:

  • Traumatic Brain Injury
  • Anaesthesia Induced Developmental Neurotoxicity
  • Hypoxic Ischaemic Encephalopathy


Research
and
Development

DISCLAIMER – IMPORTANT

ELECTRONIC VERSIONS OF THE MATERIALS YOU ARE SEEKING TO WHICH THIS GATEPOST GIVES ACCESS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY NEUROPROTEXEON LIMITED (“NPXe”) IN GOOD FAITH AND ARE FOR INFORMATION PURPOSES ONLY.
THE MATERIALS TO WHICH THIS GATEPOST GIVE ACCESS ARE NOT DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN OR RESIDENT IN (OR ORGANISED OR INCORPORATED UNDER THE LAWS OF) THE UNITED STATES OR U.S. PERSONS (AS SUCH TERM IS DEFINED IN REGULATION S (“REGULATION S”) UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)), WHEREVER LOCATED, OR PERSONS RESIDENT OR LOCATED IN AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE THE EXTENSION OF AVAILABILITY OF THE MATERIALS TO WHICH YOU ARE SEEKING ACCESS WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
The materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada, Japan, or in any jurisdiction in which such offers or sales are unlawful (the “Excluded Territories”) or to U.S. Persons (as such term is defined in Regulation S), wherever located. Any securities issued in connection with an offering have not been and will not be registered under the Securities Act or under any applicable securities laws of any state, province, territory, county or jurisdiction of the United States, Australia, Canada or Japan. Accordingly, unless an exemption under relevant securities laws is applicable, any such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such securities in, the relevant jurisdiction. There will be no public offer of securities in the United States.
The materials are only addressed to and directed at persons in member states of the European Economic Area (“EEA”) who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC and any amendments thereto including Directive 2010/73/EU to the extent implemented in the relevant EEA member state) and any relevant implementing measure in the relevant member state of the EEA (“Qualified Investors”). In addition, in the United Kingdom, the materials are being distributed only to, and are directed at Qualified Investors (as defined above) who are (a) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (b) high net worth entities, and other persons falling within Article 49(2)(a) to (d) of the Order to whom they may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). Any investment or investment activity to which these materials relates are available only to Relevant Persons in the United Kingdom and Qualified Investors in any member state of the EEA other than the United Kingdom, and will only be engaged with such persons.
If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. These materials must not be released or otherwise forwarded, distributed or sent to U.S. Persons or otherwise in or into the United States, Australia, Canada, Japan, or any jurisdiction in which such offers or sales are unlawful. Persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them to U.S Persons or otherwise in, into or from the United States, Australia, Canada or Japan.
Confirmation of understanding and acceptance of disclaimer
I warrant that I am not a resident of, or located in, the United States, Australia, Canada or Japan or any other jurisdiction where accessing these materials is unlawful, nor a U.S. Person, and I agree that I will not transmit or otherwise send any materials contained in this website to any U.S Person or any other person in the United States, Australia, Canada, Japan or any other jurisdiction where to do so would breach applicable local law or regulation.
I have read and understood the disclaimer set out above. I understand that it may affect my rights and I agree to be bound by its terms. I confirm that I am permitted to proceed to electronic versions of the materials.
NeuroproteXeon does not accept any responsibility for any contravention of applicable securities laws and regulations by individuals as a result of false information provided by such individuals.
[I ACCEPT] [DON’T ACCEPT]